Key Highlights

  • Curis shares were trading up 73.68% at $1.24, against a prior close of $0.71.
  • Volume topped 159 million shares.
  • The company and Aurigene announced an amendment to their collaboration.
  • Emavusertib is being studied in blood cancers, including AML and CNS lymphoma.
  • Third-quarter results are expected in November.

A Collaboration Amendment Sparks an Outsized Move

Curis (NASDAQ:CRIS) shares were trading up 73.68% at $1.24 on Wednesday, against a prior close of $0.71, on Volume above 159 million shares. The move followed news that the company and Aurigene amended their collaboration agreement. Terms were not part of the information available at the time of writing, so the market is reacting to the headline itself.

A broad rally in health stocks after the midterms added a tailwind, though a gain of this size is clearly specific to the stock.

Emavusertib Is the Asset Behind the Story

Curis develops targeted cancer therapies, and its lead asset is emavusertib, an oral inhibitor of IRAK4 and FLT3 licensed from Aurigene. The drug is being studied in blood cancers such as acute myeloid leukemia, myelodysplastic syndromes, primary CNS lymphoma and chronic lymphocytic leukemia, and holds Orphan Drug designations.

The collaboration with Aurigene is therefore central to the company’s outlook, which is why an amendment to it draws attention.

Tiny Team, Thin Cash Cushion, Royalty Income From Erivedge

Revenue comes mainly from Erivedge royalties tied to its Genentech and Roche collaboration. The company has about 22 employees and has relied on recent Equity and private Placement financings to fund development, which is a familiar pattern for micro-cap biotechs.

The 52-week range runs from $0.39 to $29.80, and the stock trades at a fraction of its yearly high even after today’s gain. Third-quarter results are due in November.